- Home
- News
- us virgislands
- protective immunity
Refine by
Protective Immunity Articles & Analysis: Older
32 news found
Oyster peptide Oyster peptides can help regulate blood lipids, inhibit platelet aggregation, relieve hyperglycemia, improve immunity, as well as protect and promote liver metabolism. Sea cucumber peptide In utilizing the enzyme hydrolysis technology, large proteins of sea cucumbers can be hydrolyzed into small molecular peptides. ...
This unique auto-adjuvanted antigen presentation platform has successfully demonstrated the capacity to elicit protective/neutralizing immune responses against allergens and ...
Immunotherapies are designed to restore the body’s own complex immune and defense mechanisms to recognize and destroy cancer cells. Checkpoint inhibitor therapy targets immune checkpoints, which are key regulators of the immune system that stimulate or inhibit its actions. Tumors can use these key regulators to protect ...
VX-880 is delivered by an infusion into the hepatic portal vein and requires maintenance immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or Graft-versus-Host Disease (GvHD), ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and cellular ...
VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
A recently completed Phase 2 clinical trial in COVID-19 prevention demonstrated 96% cellular immune protection efficiency to SARS-CoV-2 with the fewest and lowest adverse events of any published COVID-19 ...
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
GMT was measured across three age groups and demonstrated strong immune response after the second dose. There were no serious adverse events such as myocarditis, pericarditis, or blood clots, reported in any of the three age groups. This immunobridging trial was intended to determine if COVAXIN™ generates the same protective immunity in ...
Millions of years of evolution have taught our immune system how to protect against pathogens. Angany brings a novel generation of allergy immunotherapy where allergens are administered under the form of pseudo-pathogens to elicit a protective immune response. ...
The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. ...
The second manuscript has been published in “Vaccine” and provides important data validating the potential of V-306 to be administered ‘epicutaneously’ via skin patch delivery, as a method to boost protective immunity to RSV following initial intramuscular injection. Following administration of V-306, the immune response ...
Probiotics are beneficial forms of gut bacteria that help stimulate the natural digestive juices and enzymes that keep our digestive organs functioning properly. Microalgae are probiotic foods that have been shown to increase the amount of both Lactobacillus and bifidobacteria in the digestive tract. In addition to detoxify our body, microalgae stimulate the immune system. Must ...
Antigens are the components of vaccines that are supposed to elicit immune responses to protect against infectious pathogens or to combat diseases like cancer. The advantages of protein body-based vaccines include the large amounts of antigens that can be delivered to the body and their nanoparticulate architecture for induction of potent immune ...
Novavax' recombinant protein vaccine candidate, NVX-CoV2373, is one of four COVID-19 vaccines that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. "Novavax' addition to this important study reflects the urgency of finding innovative ways to ...
ByNovavax
Published online in Preprints with The Lancet, this vaccine's high levels of protective efficacy hold promise of becoming an important tool for global malaria eradication. ...
ByNovavax
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
Evaxion’s EDEN AI platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. It has been designed to rapidly identify those antigens that will trigger a robust protective immune response against almost any bacterial infectious ...
Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal immunity by inhibition of eATP signalling Enhancement of immune checkpoint blockade by eATP interfering biotherapeutics “We were ...